Fascin binding compounds for spinogenesis

A method of promoting spinogenesis in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I:

• or a pharmaceutically acceptable salt thereof;
• wherein A1, A2, A3, A4, A5 and A6 are independently selected from the group consisting of CH, CR3 and N, provided that no more than four of A1, A2, A3, A4, A5 and A6 are N;
• R1 is selected from the group consisting of phenyl, 5-membered heteroaryl and 6-membered heteroaryl, wherein the phenyl, 5-membered heteroaryl or 6-membered heteroaryl is optionally substituted with 1 to 3 R6;
• L2 is selected from the group consisting of a covalent bond, —NR8—, —C(O)NR8—, —NR8—, —C(O)NR8—, —NR8C(O)—, —C(O)CR82—, —CR82C(O)—, —NR8CR82—, and —CR82NR8—;
• R2 is H, C1-6 alkyl, 6- to 10-membered aryl or 5- to 10-membered heteroaryl;
• wherein the 6- to 10-membered aryl or 5- to 10-membered heteroaryl is optionally substituted with 1 to 4 R4, wherein each R4 is independently selected from the group consisting of C1-6 alkyl, C1-4 haloalkyl, phenyl (optionally substituted with C1-6 alkyl, halo, C1-4 haloalkyl, or —OH), —OH, —OR7, —SH, —SR7, —NR10R10, halo, cyano, nitro, —COH, —COR7, —CO2H, —CO2R7, —CONR10R10, —OCOR7, —OCO2R7, —OCONR10R10, —NR10COR7, —NR10CO2R7, —SOR7, —SO2R7, —SO2NR10R10, and —NR10SO2R7;
• each R3 is independently selected from the group consisting of C1-6 alkyl, C10.4 haloalkyl, —OH, —OR7, —SH, —SR7, —NR10R10, halo, cyano, nitro, —COH, —COR7, —CO2H, —CO2R7, —CONR10R10, —OCOR7, —OCO2R7, —OCONR10R10, —NR10COR7, —NR10CO2R7, —SOR7, —SO2R7, —SO2NR10R10, and —NR10SO2R7;
• q is 1, 2 or 3;
• each R6 is independently selected from the group consisting of cyano, halo, C1-6 alkyl, C1-6 haloalkyl, and —CH2OH;
• R7 is C1-6 alkyl or C1-4 haloalkyl;
• R8 is hydrogen or C1-6 alkyl;
• each R10 is independently hydrogen or C1-6 alkyl, or two R10 together with the atom(s) attached thereto form a 4- to 6-membered ring;
• and
• R11 is hydrogen or R3.